Transcerebral exchange kinetics of nitrite and calcitonin gene-related peptide in acute mountain sickness: evidence against trigeminovascular activation?

Stroke

Volumn 40, Issue 6, 2009, Pages 2205-2208

  Bailey, Damian M ^a   Taudorf, Sarah ^b   Berg, Ronan M G ^b   Jensen, Lars T ^b   Lundby, Carsten ^b   Evans, Kevin A ^a   James, Philip E ^c   Pedersen, Bente K ^b   Moller, Kirsten ^b  

^a UNIVERSITY OF GLAMORGAN   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Acute mountain sickness; Brain; Calcitonin gene related peptide; Gene related peptide; Hypoxia; Nitrite

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; NITRITE; OXYGEN; NITRIC OXIDE;

ADULT; ALTITUDE DISEASE; ARTICLE; BRAIN BLOOD FLOW; CALCULATION; CARDIOVASCULAR SYSTEM; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPOXIA; JUGULAR VEIN; KINETICS; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN TRANSPORT; RADIAL ARTERY; SYMPTOM; TRIGEMINAL NERVE; ANOXIA; BRAIN CIRCULATION; BRAIN LEVEL; LETTER; LUMINESCENCE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; QUESTIONNAIRE;

ADULT; ALTITUDE SICKNESS; ANOXIA; BRAIN CHEMISTRY; CALCITONIN GENE-RELATED PEPTIDE; CEREBROVASCULAR CIRCULATION; HEADACHE; HUMANS; KINETICS; LUMINESCENCE; MALE; NITRIC OXIDE; QUESTIONNAIRES; TRIGEMINAL NERVE;

EID: 66849135275     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.543959     Document Type: Article

References (20)

1. 1. Hackett PH, Roach RC. High-altitude illness. N Engl J Med. 2001;345: 107-114.
2. Olesen J. Revision of the international headache classification. Cephalalgia. 2001;21:261.
3. Kallenberg K, Bailey DM, Christ S, Mohr A, Roukens R, Menold E, Steiner T, Bartsch P, Knauth M. Magnetic resonance imaging evidence of cytotoxic cerebral edema in acute mountain sickness. J Cereb Blood Flow Metab. 2007;27:1064-1071.
4. Jafarian S, Gorouhi F, Salimi S, Lotfi J. Sumatriptan for prevention of acute mountain sickness: Randomized clinical trial. Ann Neurol. 2007; 62:273-277.
5. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon RO, Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med. 2003;9:1498-1505.
6. Goadsby P, Lipton R, Ferrari M. Migraine-current understanding and treatment. N Engl J Med. 2002;346:257-270.
7. Kety SS, Schmidt CF. The nitrous oxide method for the quantitative determination of cerebral blood flow in man: Theory, procedure and normal values. J Clin Invest. 1948;27:476-484.
8. Taudorf S, Berg RMG, Bailey DM, Møller K. Cerebral blood flow and oxygen metabolism measured with the Kety-Schmidt method using nitrous oxide. Acta Anaesthesiol Scand. 2009;53:159-167.
9. Rogers SC, Khalatbari A, Gapper PW, Frenneaux MP, James PE. Detection of human red blood cell-bound nitric oxide. J Biol Chem. 2005;280:26720-26728.
10. Schifter S. Circulating concentrations of calcitonin gene-related peptide (CGRP) in normal man determined with a new, highly sensitive radio- immunoassay. Peptides. 1991;12:365-369.
11. Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol. 2005;58:561-568.
12. Bailey DM, Evans KA, James PE, McEneny J, Young IS, Fall L, Gutowski M, Kewley E, McCord JM, Moller K, Ainslie PN. Altered free radical metabolism in acute mountain sickness: Implications for dynamic cerebral autoregulation and blood-brain barrier function. J Physiol. 2009; 587:73-85.
13. Bailey DM, Roukens R, Knauth M, Kallenberg K, Christ S, Mohr A, Genius J, Storch-Hagenlocher B, Meisel F, McEneny J, Young IS, Steiner T, Hess K, Bartsch P. Free radical-mediated damage to barrier function is not associated with altered brain morphology in high-altitude headache. J Cereb Blood Flow Metab. 2006;26:99-111.
14. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183-187.
15. Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G, Trequattrini A, Palumbo R. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995;15:384-390.
16. Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia. 2000;20:907-918.
17. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. Cgrp may play a causative role in migraine. Cephalalgia. 2002;22:54-61.
18. Olesen J, Diener H-C, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM, the BBSCPoCSG. Calcitonin gene-related peptide receptor antagonist bibn 4096 bs for the acute treatment of migraine. N Engl J Med. 2004;350:1104-1110.
19. Kraenzlin ME, Ch'ng JL, Mulderry PK, Ghatei MA, Bloom SR. Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones. Regul Pept. 1985;10:189-197.
20. Strecker T, Dux M, Messlinger K. Increase in meningeal blood flow by nitric oxide-interaction with calcitonin gene-related peptide receptor and prostaglandin synthesis inhibition. Cephalalgia. 2002;22:233-241.